Prescription Drug Matzim LA Extended-Release Tablets Recalled for Failed Dissolution
Teva Pharmaceuticals is recalling Matzim LA (Diltiazem Hydrochloride) 180 mg tablets because they failed to meet dissolution specifications. The recall affects approximately 8,022 bottles distributed nationwide in the United States and Puerto Rico.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II designation indicates potential for adverse health consequences; this is a cardiac medication with failed dissolution specifications, representing a risk-of-harm product where no illnesses or injuries have been reported, consistent with High (Score 3) per the severity rubric.
Plain-English summary
Teva Pharmaceuticals USA Inc is recalling Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, due to failed dissolution specifications. The affected tablets did not meet dissolution specification limits.
The recall involves approximately 8,022 bottles with lot number 1411593A and expiration date 09/22. The product was distributed nationwide in the United States and Puerto Rico.
The extended-release formulation with NDC number 52544-691-30 is manufactured by Actavis Laboratories FL, Inc. and distributed by Actavis Pharma, Inc. These tablets are prescription-only medication.
The recalled product
- Product
- MATZIM LA (DILTIAZEM HYDROCHLORIDE)
- Brand
- MATZIM LA
- Manufacturer
- Teva Pharmaceuticals USA Inc
- Category
- Drug — Extended-Release Tablet
- Hazard
- dissolution-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 1411593A
- Exp 09/22
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01